Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
NCT03905603Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Oct 2019
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of repository corticotropin injection and recombinant human chorionic gonadotrophin, sponsored by University of Virginia. Primary endpoints: Change in calculated free testosterone concentrations at 24 hours, Mean luteinizing hormone (LH) concentrations at 12 hours and 3 more. Started Oct 2019; status: recruiting.
02
Drugs
repository corticotropin injectionrecombinant human chorionic gonadotrophin
Beyond the preview
Go deeper on NCT03905603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905603.